^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Q-1802

    i
    Other names: Q-1802
    Company:
    Viva Biotech
    Drug class:
    PD-L1 inhibitor, CLDN18.2 inhibitor
    Related drugs:
    16d
    Development and validation of ELISA method for quantification of Q-1802 in serum and its application to pharmacokinetic study in ICR Mouse. (PubMed, J Pharm Biomed Anal)
    In conclusion, we have developed and validated a highly sensitive and selective method for measuring Q-1802 in ICR mouse serum. The development and validation steps of assays met the required criteria for validation, which suggested that these can be applied to quantify Q-1802, as well as in PK studies.
    PK/PD data • Preclinical • Journal
    |
    CLDN18 (Claudin 18)
    |
    Q-1802
    9ms
    The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors (clinicaltrials.gov)
    P1/2, N=72, Recruiting, QureBio Ltd.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 negative
    |
    capecitabine • oxaliplatin • Q-1802
    9ms
    A Study of Q-1802 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=66, Recruiting, QureBio Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Jan 2023 --> Jul 2024 | Trial primary completion date: Aug 2022 --> Apr 2024
    Enrollment open • Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Q-1802
    over1year
    Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors. (ASCO-GI 2023)
    Interim data from the present phase 1 study, demonstrate that Q-1802 has excellent preliminary safety, tolerability and preliminary anti-tumor activity up to doses of 20 mg/kg. The dose extension is still ongoing. Clinical trial information: NCT04856150.
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    CLDN18.2 expression • CLDN18.2 positive
    |
    Q-1802
    2years
    Safety results of Q-1802, a Claudin18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors in a phase 1 study. (ASCO 2022)
    Q-1802 bsABs has presented safe and well-tolerated profile up to doses of 10 mg/kg. The dose escalation is still in progress.
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18) • CLDN8 (Claudin 8)
    |
    CLDN18.2 expression
    |
    Q-1802
    3years
    A Study of Q-1802 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=66, Not yet recruiting, QureBio Ltd.
    Clinical • New P1 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Q-1802